Skip to main content
SpringerLink
Log in

Isolierte arterielle Infusion von Extremitäten

  • Chapter
Regionale Therapie maligner Tumoren

  • 1144 Accesses

Zusammenfassung

Die Behandlung von Patienten mit fortgeschrittenen oder rezidivierenden Malignomen der Extremitäten ist aufgrund der Größe und Anzahl der Satelliten- und/oder In-Transit-Metastasen beim malignen Melanom oder wegen der Invasion des Tumors in angrenzende Strukturen bei Weichteilsarkomen oft eine Herausforderung. Vor Mitte der 1950er Jahre war die Amputation der betroffenen Extremität die Therapie der Wahl. Nach der Einführung der isolierten Extremitätenperfusion (ILP) wurde dieser verstümmelnde Eingriff bei der Mehrzahl der Patienten vermieden [1].

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 139.00
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
Hardcover Book
USD 159.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

Literatur

  1. Creech O, Jr., Ryan RF, Krementz ET. Regional chemotherapy by isolated perfusion in the treatment of melanoma of the extremities. Plast Reconstr Surg Transplant Bull. Oct 1961;28:333–346.

    Google Scholar 

  2. Noorda EM, Vrouenraets BC, Nieweg OE, Van Coevorden F, Kroon BB. Isolated limb perfusion: what is the evidence for its use? Ann Surg Oncol. Sep 2004;11(9):837–845.

    Google Scholar 

  3. Thompson JF, Hunt JA, Shannon KF, Kam PC. Frequency and duration of remission after isolated limb perfusion for melanoma. Arch Surg. Aug 1997;132(8):903–907.

    Google Scholar 

  4. Vrouenraets BC, Nieweg OE, Kroon BB. Thirty-five years of isolated limb perfusion for melanoma: indications and results. Br J Surg. Oct 1996;83(10):1319–1328.

    Google Scholar 

  5. Karakousis CP, Kanter PM, Lopez R, Moore R, Holyoke ED. Modes of regional chemotherapy. J Surg Res. Feb 1979; 26(2):134–141.

    Google Scholar 

  6. Bland KI, Kimura AK, Brenner DE, et al. A phase II study of the efficacy of diamminedichloroplatinum (cisplatin) for the control of locally recurrent and intransit malignant melanoma of the extremities using tourniquet outflowocclusion techniques. Ann Surg. Jan 1989;209(1):73–80.

    Google Scholar 

  7. Karakousis CP, Kanter PM, Park HC, Sharma SD, Moore R, Ewing JH. Tourniquet infusion versus hyperthermic perfusion. Cancer. Mar 1 1982;49(5):850–858.

    Google Scholar 

  8. Thompson JF, Kam PC, Waugh RC, Harman CR. Isolated limb infusion with cytotoxic agents: a simple alternative to isolated limb perfusion. Semin Surg Oncol. Apr-May 1998;14(3):238–247.

    Google Scholar 

  9. Thompson JF, Waugh RC, Saw RP, Kam PC. Isolated limb infusion with melphalan for recurrent limb melanoma: a simple alternative to isolated limb perfusion. Reg Cancer Treat. 1994;7:188–192.

    Google Scholar 

  10. Santillan AA, Delman KA, Beasley GM, et al. Predictive Factors of Regional Toxicity and Serum Creatine Phosphokinase Levels After Isolated Limb Infusion for Melanoma: A Multi-Institutional Analysis. Ann Surg Oncol. Jun 19 2009;16(9):2570–2578.

    Google Scholar 

  11. Kroon HM, Moncrieff M, Kam PC, Thompson JF. Outcomes following isolated limb infusion for melanoma. A 14-year experience. Ann Surg Oncol. Nov 2008;15(11):3003–3013.

    Google Scholar 

  12. Lindner P, Doubrovsky A, Kam PC, Thompson JF. Prognostic factors after isolated limb infusion with cytotoxic agents for melanoma. Ann Surg Oncol. Mar 2002;9(2):127–136.

    Google Scholar 

  13. Moncrieff MD, Kroon HM, Kam PC, Stalley PD, Scolyer RA, Thompson JF. Isolated limb infusion for advanced soft tissue sarcoma of the extremity. Ann Surg Oncol. Oct 2008;15(10):2749–2756.

    Google Scholar 

  14. Thompson JF, Kam PC. Isolated limb infusion for melanoma: a simple but effective alternative to isolated limb perfusion. J Surg Oncol. Oct 1 2004;88(1):1–3.

    Google Scholar 

  15. Thompson JF, Lai DT, Ingvar C, Kam PC. Maximizing efficacy and minimizing toxicity in isolated limb perfusion for melanoma. Melanoma Res. Mar 1994;4 Suppl 1:45–50.

    Google Scholar 

  16. Wieberdink J, Benckhuysen C, Braat RP, van Slooten EA, Olthuis GA. Dosimetry in isolation perfusion of the limbs by assessment of perfused tissue volume and grading of toxic tissue reactions. Eur J Cancer Clin Oncol. Oct 1982; 18(10):905–910.

    Google Scholar 

  17. Lai DT, Ingvar C, Thompson JF. The value of monitoring serum creatine phosphokinase values following hyperthermic isolated limb perfusion for melanoma. Reg Cancer Treat. 1993;6:36–39.

    Google Scholar 

  18. Kroon HM, Moncrieff M, Kam PC, Thompson JF. Factors predictive of acute regional toxicity after isolated limb infusion with melphalan and actinomycin D in melanoma patients. Ann Surg Oncol. May 2009;16(5):1184–1192.

    Google Scholar 

  19. Huismans AM, Kroon HM, Kam PC, Thompson JF. Does increased experience with isolated limb infusion for advanced limb melanoma influence outcome? A comparison of two treatment periods at a single institution. Ann Surg Oncol. Jul 2011;18(7):1877–1883.

    Google Scholar 

  20. Skarsgard LD, Skwarchuk MW, Vinczan A, Kristl J, Chaplin DJ. The cytotoxicity of melphalan and its relationship to pH, hypoxia and drug uptake. Anticancer Res. Jan-Feb 1995;15(1):219–223.

    Google Scholar 

  21. de Wilt JH, Manusama ER, van Tiel ST, van Ijken MG, ten Hagen TL, Eggermont AM. Prerequisites for effective isolated limb perfusion using tumour necrosis factor alpha and melphalan in rats. Br J Cancer. Apr 1999;80(1-2):161–166.

    Google Scholar 

  22. Siemann DW, Chapman M, Beikirch A. Effects of oxygenation and pH on tumour cell response to alkylating chemotherapy. Int J Radiat Oncol Biol Phys. Feb 1991;20(2):287–289.

    Google Scholar 

  23. Chaplin DJ, Acker B, Olive PL. Potentiation of the tumour cytotoxicity of melphalan by vasodilating drugs. Int J Radiat Oncol Biol Phys. May 1989;16(5):1131–1135.

    Google Scholar 

  24. Kroon BB. Regional isolation perfusion in melanoma of the limbs; accomplishments, unsolved problems, future. Eur J Surg Oncol. Apr 1988;14(2):101–110.

    Google Scholar 

  25. Thompson JF, Ramzan I, Kam PCA, Yau DF. Pharmacokinetics of melphalan during isolated limb infusion for melanoma. Reg Cancer Treat. 1996;9:13–16.

    Google Scholar 

  26. Roberts MS, Wu ZY, Siebert GA, Anissimov YG, Thompson JF, Smithers BM. Pharmacokinetics and pharmacodynamics of melphalan in isolated limb infusion for recurrent localized limb malignancy. Melanoma Res. Aug 2001; 11(4):423–431.

    Google Scholar 

  27. Schraffordt Koops H, Lejeune FJ, Kroon BBR, Klaase JM, Hoekstra HJ. Isolated limb perfusion for melanoma: technical aspects. In: Thompson JF, Morton DL, Kroon BBR, eds. Textbook of Melanoma. London: Martin Dunitz; 2004: 404–409.

    Google Scholar 

  28. Vrouenraets BC, Klaase JM, Nieweg OE, Kroon BB. Toxicity and morbidity of isolated limb perfusion. Semin Surg Oncol. Apr-May 1998;14(3):224–231.

    Google Scholar 

  29. Thompson JF, Kam PC, De Wilt JH, Lindner P. Isolated limb infusion for melanoma. In: Thompson JF, Morton DL, Kroon BBR, eds. Textbook of Melanoma. London: Martin Dunitz; 2004:429–437.

    Google Scholar 

  30. Kroon BB, Noorda EM, Vrouenraets BC, Nieweg OE. Isolated limb perfusion for melanoma. J Surg Oncol. Apr 2002;79(4):252–255.

    Google Scholar 

  31. Wu ZY, Smithers BM, Parsons PG, Roberts MS. The effects of perfusion conditions on melphalan distribution in the isolated perfused rat hindlimb bearing a human melanoma xenograft. Br J Cancer. 1997;75(8):1160–1166.

    Article  PubMed  CAS  Google Scholar 

  32. Roberts MS, Wu ZY, Siebert GA, Thompson JF, Smithers BM. Saturable dose-response relationships for melphalan in melanoma treatment by isolated limb infusion in the nude rat. Melanoma Res. Dec 2001;11(6):611–618.

    Google Scholar 

  33. Cheng TY, Grubbs E, Abdul-Wahab O, et al. Marked variability of melphalan plasma drug levels during regional hyperthermic isolated limb perfusion. Am J Surg. Nov 2003;186(5):460–467.

    Google Scholar 

  34. McMahon N, Cheng TY, Beasley GM, et al. Optimizing melphalan pharmacokinetics in regional melanoma therapy: does correcting for ideal body weight alter regional response or toxicity? Ann Surg Oncol. Apr 2009;16(4): 953– 961.

    Google Scholar 

  35. Beasley GM, Petersen RP, Yoo J, et al. Isolated limb infusion for in-transit malignant melanoma of the extremity: a well-tolerated but less effective alternative to hyperthermic isolated limb perfusion. Ann Surg Oncol. Aug 2008; 15(8):2195–2205.

    Google Scholar 

  36. Klaase JM, Kroon BB, Beijnen JH, van Slooten GW, van Dongen JA. Melphalan tissue concentrations in patients treated with regional isolated perfusion for melanoma of the lower limb. Br J Cancer. Jul 1994;70(1):151–153.

    Google Scholar 

  37. Huismans AM, Kroon HM, Haydu LE, Kam PCA, Thompson JF. Correcting melphalan dose for ideal body weight in isolated limb infusion for melanoma; does it influence toxicity or response? Ann Surg Oncol. 2012:in press.

    Google Scholar 

  38. Bonenkamp JJ, Thompson JF, de Wilt JH, Doubrovsky A, de Faria Lima R, Kam PC. Isolated limb infusion with fotemustine after dacarbazine chemosensitisation for inoperable loco-regional melanoma recurrence. Eur J Surg Oncol. Dec 2004;30(10):1107–1112.

    Google Scholar 

  39. Yoshimoto Y, Augustine CK, Yoo JS, et al. Defining regional infusion treatment strategies for extremity melanoma: comparative analysis of melphalan and temozolomide as regional chemotherapeutic agents. Mol Cancer Ther. May 2007;6(5):1492–1500.

    Google Scholar 

  40. Ueno T, Ko SH, Grubbs E, et al. Modulation of chemotherapy resistance in regional therapy: a novel therapeutic approach to advanced extremity melanoma using intraarterial temozolomide in combination with systemic O6- benzylguanine. Mol Cancer Ther. Mar 2006;5(3):732–738.

    Google Scholar 

  41. Grubbs EG, Ueno T, Abdel-Wahab O, et al. Modulation of resistance to regional chemotherapy in the extremity melanoma model. Surgery. Aug 2004;136(2):210–218.

    Google Scholar 

  42. Beasley G, Tyler D. Standardizing Regional Therapy: Developing a Consensus on Optimal Utilization of Regional Chemotherapy Treatments in Melanoma. ann Surg Oncol. 2011;18:1814–1818.

    Article  PubMed  Google Scholar 

  43. Brady MS, Brown K, Patel A, Fisher C, Marx W. Isolated limb infusion with melphalan and dactinomycin for regional melanoma and soft-tissue sarcoma of the extremity: final report of a phase II clinical trial. Melanoma Res. Apr 2009; 19(2):106–111.

    Google Scholar 

  44. Raymond AK, Beasley GM, Broadwater G, et al. Current trends in regional therapy for melanoma: lessons learned from 225 regional chemotherapy treatments between 1995 and 2010 at a single institution. J Am Coll Surg. Aug 2011;213(2):306–316.

    Google Scholar 

  45. Hegazy MA, Kotb SZ, Sakr H, et al. Preoperative isolated limb infusion of Doxorubicin and external irradiation for limb-threatening soft tissue sarcomas. Ann Surg Oncol. Feb 2007;14(2):568–576.

    Google Scholar 

  46. Damian DL, Barnetson RS, Rose BR, Bonenkamp JJ, Thompson JF. Treatment of refractory hand warts by isolated limb infusion with melphalan and actinomycin D. Australas J Dermatol. May 2001;42(2):106–109.

    Google Scholar 

  47. Damian DL, Barnetson RS, Thompson JF. Treatment of refractory chromomycosis by isolated limb infusion with melphalan and actinomycin D. J Cutan Med Surg. Jan-Feb 2006;10(1):48–51.

    Google Scholar 

  48. Elhassadi E, Egan E, O'Sullivan G, Mohamed R. Isolated limb infusion with cytotoxic agent for treatment of localized refractory cutaneous T-cell lymphoma. 5. Isolated Limb Infusion as an induction therapy Aug 2006;28(4): 279–281.

    Google Scholar 

  49. Turaga KK, Beasley GM, Kane JM, 3rd, et al. Limb preservation with isolated limb infusion for locally advanced nonmelanoma cutaneous and soft-tissue malignant neoplasms. Arch Surg. Jul 2011;146(7):870–875.

    Google Scholar 

  50. Grunhagen DJ, de Wilt JH, van Geel AN, Eggermont AM. Isolated limb perfusion for melanoma patients--a review of its indications and the role of tumour necrosis factoralpha. Eur J Surg Oncol. May 2006;32(4):371–380.

    Google Scholar 

  51. Noorda EM, Vrouenraets BC, Nieweg OE, van Geel BN, Eggermont AM, Kroon BB. Isolated limb perfusion for unresectable melanoma of the extremities. Arch Surg. Nov 2004;139(11):1237–1242.

    Google Scholar 

  52. Barbour AP, Thomas J, Suffolk J, Beller E, Smithers BM. Isolated limb infusion for malignant melanoma: predictors of response and outcome. Ann Surg Oncol. Dec 2009; 16(12):3463–3472.

    Google Scholar 

  53. Mian R, Henderson MA, Speakman D, Finkelde D, Ainslie J, McKenzie A. Isolated limb infusion for melanoma: a simple alternative to isolated limb perfusion. Can J Surg. Jun 2001;44(3):189–192.

    Google Scholar 

  54. Feldman AL, Alexander HR, Jr., Bartlett DL, Fraker DL, Libutti SK. Management of extremity recurrences after complete responses to isolated limb perfusion in patients with melanoma. Ann Surg Oncol. Sep 1999;6(6):562–567.

    Google Scholar 

  55. Kroon HM, Lin DY, Kam PC, Thompson JF. Efficacy of repeat isolated limb infusion with melphalan and actinomycin D for recurrent melanoma. Cancer. 2009; 115(9): 1932–1940.

    Article  PubMed  CAS  Google Scholar 

  56. Kroon HM, Lin DY, Kam PC, Thompson JF. Major amputation for irresectable extremity melanoma after failure of isolated limb infusion. Ann Surg Oncol. Jun 2009;16(6): 1543–1547.

    Google Scholar 

  57. Beasley GM, McMahon N, Sanders G, et al. A phase 1 study of systemic ADH-1 in combination with melphalan via isolated limb infusion in patients with locally advanced in-transit malignant melanoma. Cancer. Oct 15 2009; 115(20):4766–4774.

    Google Scholar 

  58. Beasley GM, Riboh JC, Augustine CK, et al. Prospective multicenter phase II trial of systemic ADH-1 in combination with melphalan via isolated limb infusion in patients with advanced extremity melanoma. J Clin Oncol. Mar 20 2011;29(9):1210–1215.

    Google Scholar 

  59. Eisen T, Marais R, Affolter A, et al. Sorafenib and dacarbazine as first-line therapy for advanced melanoma: phase I and open-label phase II studies. Br J Cancer. Jul 26 2011;105(3):353–359.

    Google Scholar 

  60. McDermott DF, Sosman JA, Gonzalez R, et al. Doubleblind randomized phase II study of the combination of sorafenib and dacarbazine in patients with advanced melanoma: a report from the 11715 Study Group. J Clin Oncol. May 1 2008;26(13):2178–2185.

    Google Scholar 

  61. McMahon N, Beasley G, Sanders G, et al. A phase I study of systemic sorafenib in combination with isolated limb infusion with melphalan (ILI-M) in patients (pts) with locally advanced in-transit melanoma (abstract). J Clin Oncol. 2009;27 (15 Suppl).

    Google Scholar 

  62. Augustine CK, Toshimitsu H, Jung SH, et al. Sorafenib, a multikinase inhibitor, enhances the response of melanoma to regional chemotherapy. Mol Cancer Ther. Jul 2010;9(7):2090–2101.

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Melanoma Institute Australia, 40 Rocklands Road, 2060, North Sydney New South Wales, Australien

    Anna M. Huismans MD

  2. Melanoma Institute Australia, 40 Rocklands Road, North Sydney, 2060, New South Wales, Australien

    Hidde M. Kroon MD,PhD

  3. Department of Surgery, Leiden University Medical Center, Albinusdreef 2, 2333 ZA, Leiden, Niederlande

    Hidde M. Kroon MD,PhD

  4. Sydney Medical School, The University of Sydney, Sydney New South Wales, Australien

    Prof. Peter C.A. Kam

  5. Melanoma Institute Australia, 40 Rocklands Road, 2060, North Sydney New South Wales, Australien

    Prof. John F. Thompson

Authors
  1. Anna M. Huismans MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Hidde M. Kroon MD,PhD
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Prof. Peter C.A. Kam
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Prof. John F. Thompson
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. Medias Klinikum Burghausen, Burghausen

    Karl Reinhard Aigner

  2. University of Sydney, Sydney, Australia

    Frederick O. Stephens

  3. Universitätsklinikum Frankfurt, Frankfurt

    Thomas J. Vogl

  4. Universitätsklinikum Gießen, Gießen

    Winfried Padberg

Rights and permissions

Reprints and permissions

Copyright information

© 2013 Springer-Verlag Berlin Heidelberg

About this chapter

Cite this chapter

Huismans, A.M., Kroon, H.M., Kam, P.C., Thompson, J.F. (2013). Isolierte arterielle Infusion von Extremitäten. In: Aigner, K.R., Stephens, F.O., Vogl, T.J., Padberg, W. (eds) Regionale Therapie maligner Tumoren. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-642-35014-6_26

Download citation

  • DOI: https://doi.org/10.1007/978-3-642-35014-6_26

  • Publisher Name: Springer, Berlin, Heidelberg

  • Print ISBN: 978-3-642-35013-9

  • Online ISBN: 978-3-642-35014-6

  • eBook Packages: Medicine (German Language)

Publish with us

Policies and ethics

Search

Navigation